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Abstract
The development of treatments for idiopathic pulmonary fibrosis (IPF) has been often disappointing. Building on
authorized treatments that can benchmark the validity of treatment effect measures, the time has come to
standardize endpoints and achieve consensus on their use for different clinical questions and specific IPF
phenotypes. In order to facilitate the development of new medicines for IPF it is crucial that the knowledge
of the disease and lessons learnt from past trials are taken forward to create international trial networks with
involvement of patients, including biobanks and clinical data collection through a multinational registry.
Interaction with regulators may be useful to align the initiatives of academia and pharmaceutical companies
with the bodies ultimately responsible for licensing new products. Interaction can occur through the use of
qualification programs for biomarkers and endpoints, and participation in innovative regulatory pathways and
initiatives. Finally, the experience of IPF should be used to benefit even rarer interstitial lung diseases for
which no treatment is available, including pediatric interstitial lung diseases. This commentary provides a
perspective on the hurdles slowing the development and regulatory approval of medicines for IPF, and
encourages close cooperation between investigators and drug regulators.
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Background
The development of new medicines is characterized by
very high attrition rates, with up to 10,000 compounds
failing to show clinical efficacy per each new medicine
reaching the market. Failure occurs mainly during trans-
lation from preclinical to clinical development and in
clinical phase II, with efficacy rather than safety the most
common cause of attrition [1, 2]. The respiratory field is
no exception, with one of the lowest numbers of new
medicines authorized in the past 40 years among all
medical fields [3].
In this landscape, until recently no pharmacological
treatment was available for idiopathic pulmonary fibrosis
(IPF), a rare disease of largely unknown cause with me-
dian survival estimated at about 3 years from diagnosis
[4]. After a decade of failed clinical development, pirfeni-
done (Esbriet) obtained marketing authorization in
Europe in February 2011 and nintedanib (OFEV) in
2015. Past failures have been attributed to the heteroge-
neous pathogenesis of the disease, the inappropriateness
of study designs and endpoints used in clinical trials
[5–7], and the lack of merit of the products studied,
which in many cases were repurposed and not specif-
ically developed for IPF.
While pirfenidone and nintedanib have proven to slow
the decline of lung function in the clinical trials on
which their approval was based [8], their effects on the
long-term prognosis of the disease are still unknown.
This, together with the emerging evidence of different
phenotypes in IPF [9], and the lack of treatments for
interstitial lung diseases (ILDs) other than IPF, renders it
an area of highly unmet therapeutic need.
IPF drug discovery between present and future
To date, 12 medicinal products, most in preclinical
phase of development, have obtained orphan designation
from the European Medicines Agency (EMA) [10] for
the treatment of IPF. While not compulsory, it is in the
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interest of companies to obtain orphan designation, be-
cause it allows them to apply for clinical development
incentives and for fee reductions in regulatory proce-
dures. The number of designated medicines, although
not a proxy of pharmaceutical development in a strict
sense, provides a trend of the development in specific
diseases. The number of orphan designations for IPF
compares unfavorably with that of other rare respiratory
diseases such as cystic fibrosis, with 42 designations
[11], and pulmonary arterial hypertension, where six out
of 15 products designated as orphans in the EU in
the past ten years have already obtained marketing
authorization [12].
Traditionally, pharmaceutical development starts with
the selection of scientifically robust therapeutic targets
and of the compounds with the highest activity on the
selected target(s). While this may still be valid in dis-
eases characterized by good correlation between geno-
type, molecular phenotype, and clinical phenotype, in
complex trait diseases such as IPF, determined by mul-
tiple genes and variable influence by the environment,
drug discovery tools commonly used to select and valid-
ate targets at preclinical level, such as high throughput
compound profiling in cell-based assays [13, 14], may
prove unsuccessful.
Alternative approaches for identifying therapeutic tar-
gets in IPF should be encouraged, including those based
on system biology and integrative omics. So far a hand-
ful of studies have investigated omics evidence in IPF,
with hypothesis-generating results such as the discovery
of genetic variants associated with alterations of lung
host defense [15] (microbiome), of transcriptional effects
of autoantibodies against collagen V [16] (“antibodome”),
and of genomic and histology-based specific patterns of
disease [17]. Innovative drug development would require
data knowledge integration, connecting genetic and mo-
lecular aspects of IPF with the network of downstream
events and the clinical manifestations of the disease and
its progression. It is worth broadly applying integrative ap-
proaches to progressive pulmonary fibrosis [18] rather
than limiting them to IPF, because many pathogenetic
aspects are common to different disease entities character-
ized by pulmonary fibrosis, including the role of epithelial
cells, DNA repair and cell senescence, and the endoplas-
mic reticulum [15, 19].
With translational failure of many IPF pharmaceutical
pipelines, recurrent criticism arises toward the most
widely used in vivo preclinical proof of concept, the
bleomycin challenge rodent model. Indeed, none out of
almost 300 compounds demonstrating efficacy in the
bleomycin model was then efficacious in clinical trials
[20]. The model was, however, used in the preclinical
development of pirfenidone [21] and nintedanib [22],
compounds with a successful clinical development. To
clarify the usefulness and limitations of the bleomycin
model as proof of concept in IPF and other ILDs,
standardization is needed of methodological aspects,
such as the timing of administration of candidate
products—which are currently administered in most
preclinical studies before or immediately after bleomycin
challenge [20] as opposed to the clinical situation where
lung fibrosis is already present at the start of treatment.
At the same time, there is urgent need of preclinical
proof-of-concept tools going beyond animal models to
include the use of human tissue-based and system biol-
ogy readouts.
The future of clinical development in IPF
and beyond
In addition to the complexity induced by pathogenetic
and clinical heterogeneity, the development of medicines
for the treatment of IPF suffers from the hurdles charac-
teristic of rare diseases, where small numbers of patients
limit the feasibility of adequately powered trials, the
validation of endpoints and biomarkers [23], and the use
of hard endpoints such as mortality. From a regulatory
perspective, additional factors complicating the clinical
development in IPF include changes over time in case
definition and lack of consistency in clinical trial
endpoints.
The recent consensus on imaging-based diagnosis [24]
may facilitate the conduct of IPF trials in clearly defined
study populations. On the other hand, the great hetero-
geneity in outcome measures used across clinical trials
has largely limited the feasibility to conclusively assess
the validity of most of them. Indeed, while slowing the
decline of forced vital capacity was accepted as the pri-
mary endpoint for the regulatory approval of pirfenidone
and nintedanib [8], there is not yet consensus on its
minimal clinically important difference [25]. Mortality,
used mostly as a secondary endpoint, has also been mea-
sured inconsistently in IPF trials, as all-causes mortality,
IPF-specific mortality, time to death, progression-free
survival, or survival time [7]. Finally, composite end-
points have been suggested as a way to improve trial
efficiency and sensitivity to drug effect [7]; however, po-
tentially interesting measures in composite endpoints,
such as symptoms and clinical worsening, have not been
validated in IPF.
A recent consensus group proposing provisional core
sets of domains and instruments for clinical trials in
connective tissue disease-related ILDs and IPF con-
cluded that none of the proposed endpoints were ideal,
or fully validated [26]. Global collaborative work for val-
idation and standardization of endpoints for regulatory
use is needed to facilitate the clinical development and
the approval of new medicines in IPF. This is warranted
by the increasing complexity of clinical trials, where
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efficacy will now have to be established on top of, or in
comparison to, the authorized treatments [27]. The
consistent use of standardized endpoints across trials
would improve comparability of compounds during pre-
licensing clinical development, and provide continuity in
the measurement of treatment effects through the whole
lifecycle of medicinal products. This would allow the
harmonization of the assessment of regulatory, health
technology assessment, and payers’ bodies on the thera-
peutic added value of different products, and increase
clarity on the clinical benefit for prescribing physicians
and patients.
Ideally, outcome measures would be chosen from
among those that can be monitored in patients’ regis-
tries, to align measures of natural history of the disease
with disease progression parameters measurable in clin-
ical trials. Initiatives are ongoing at EMA to explore the
use of registry data in the frame of regulatory procedures
[28], in particular for the establishment of real-life post-
approval confirmation of effectiveness. A handful of
national IPF registries exist in Europe [29]; however, a
European rather than national dimension would be
needed, ideally integrated with the recently proposed ini-
tiatives of an IPF clinical trial network [30]. The partici-
pation of patients in international disease networks is
crucial to the development of patient-reported outcome
measures, at present poorly developed in IPF, and in line
with current initiatives incorporating patients’ views into
the benefit–risk assessment of medicines.
Among the initiatives facilitating the approval of new
medicines, early access regulatory pathways, such as the
adaptive pathway in pilot phase in Europe [31], aim to
optimize development by balancing the need for timely
patient access with the importance of providing
adequate, evolving information on a medicine’s benefit
and risk, including collection of real-world data post-
authorization to complement randomized clinical trials
data. IPF appears to be a potential candidate in this
respect, because the development of medicines initially
developed for IPF could be gradually expanded to other
target populations, e.g., ILDs other than IPF, for most of
which currently no treatment exists, including pediatric
ILDs.
Conclusions
Global collaborative efforts are warranted to facilitate
the development of new medicines for IPF, including
data knowledge integration from genomics to clinical
phenotypes. Lessons from past clinical trials should be
used to create international trial networks with involve-
ment of patients, including data collection through bio-
banks and a European registry, and for standardization
of outcome measures. Interaction with the regulators for
fostering the approval of new medicines can occur
through qualification programs for biomarkers and end-
points, and participation in innovative regulatory path-
ways and initiatives. Finally, the experience of IPF
should be applied to the development of medicines for
ILDs for which no treatment is available, including
pediatric ILDs.
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